SG11201807023QA - Compositions and methods for preventing and/or treating vitamin b12 deficiency - Google Patents

Compositions and methods for preventing and/or treating vitamin b12 deficiency

Info

Publication number
SG11201807023QA
SG11201807023QA SG11201807023QA SG11201807023QA SG11201807023QA SG 11201807023Q A SG11201807023Q A SG 11201807023QA SG 11201807023Q A SG11201807023Q A SG 11201807023QA SG 11201807023Q A SG11201807023Q A SG 11201807023QA SG 11201807023Q A SG11201807023Q A SG 11201807023QA
Authority
SG
Singapore
Prior art keywords
international
deficiency
pct
preventing
treating vitamin
Prior art date
Application number
SG11201807023QA
Inventor
Vos Willem Meindert De
Original Assignee
Caelus Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caelus Pharmaceuticals B V filed Critical Caelus Pharmaceuticals B V
Publication of SG11201807023QA publication Critical patent/SG11201807023QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111110111101110101011111010111110111010111111011101111101101111101111011111 International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/146580 Al 31 August 2017 (31.08.2017) WIPO I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 35/74 (2015.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/NL2017/050119 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 27 February 2017 (27.02.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 2016323 25 February 2016 (25.02.2016) NL kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: (72) CAELUS PHARMACEUTICALS B.V. TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [NL/NL]; 50, Rondweg, 3474 KG Zegveld (NL). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Inventor: DE VOS, Willem Meindert; 77, Oude Ben- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, nekomseweg, 6717 LM Ede (NL). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (74) Agent: KINGMA, Rd.; P.O. Box 3241, 2280 GE Rijswijk GW, KM, ML, MR, NE, SN, TD, TG). (NL). Published: (81) Designated States (unless otherwise indicated, for every with international search report (Art. 21(3)) kind of national protection available): AE, AG, AL, AM, Il © GC ir) ,tD iv 1-1 IN 1-1 (54) Title: COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING VITAMIN B12 DEFICIENCY 0 N (57) : A method for preventing and/or treating vitamin B12 deficiency is taught. The method comprises administering a en. ) composition comprising pseudovitamin B12 producing bacteria, optionally in conjunction with mucin-degrading and/or propionate- producing bacteria, to a subject in need thereof. The method is particularly suitable for administration to subjects suffering from vit- amin B12 deficiency due to metformintreatment fortype-2 diabetes, and to subjects having undergone bariatric surgery.
SG11201807023QA 2016-02-25 2017-02-27 Compositions and methods for preventing and/or treating vitamin b12 deficiency SG11201807023QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2016323 2016-02-25
PCT/NL2017/050119 WO2017146580A1 (en) 2016-02-25 2017-02-27 Compositions and methods for preventing and/or treating vitamin b12 deficiency

Publications (1)

Publication Number Publication Date
SG11201807023QA true SG11201807023QA (en) 2018-09-27

Family

ID=56507778

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807023QA SG11201807023QA (en) 2016-02-25 2017-02-27 Compositions and methods for preventing and/or treating vitamin b12 deficiency

Country Status (12)

Country Link
US (1) US10857189B2 (en)
EP (1) EP3419637B1 (en)
JP (2) JP7012651B2 (en)
KR (1) KR20180113535A (en)
CN (1) CN108697742A (en)
AU (1) AU2017222990A1 (en)
BR (1) BR112018017233A2 (en)
CA (1) CA3014525A1 (en)
ES (1) ES2865477T3 (en)
RU (1) RU2730870C2 (en)
SG (1) SG11201807023QA (en)
WO (1) WO2017146580A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113730442A (en) 2014-10-31 2021-12-03 潘德勒姆治疗公司 Methods and compositions relating to microbial treatment and diagnosis of disorders
SG11201807023QA (en) 2016-02-25 2018-09-27 Caelus Pharmaceuticals B V Compositions and methods for preventing and/or treating vitamin b12 deficiency
AU2017251253B2 (en) * 2016-04-11 2023-01-05 Wageningen Universiteit Novel bacterial species
CA3073838A1 (en) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
CA3106315A1 (en) * 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307026D0 (en) * 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
BR112014004890A8 (en) 2011-08-30 2018-02-06 Acad Medisch Ct BACTERIA, PHARMACEUTICAL, FOOD OR FEED COMPOSITION, AND USE OF THE BACTERIA
ES2708699T3 (en) 2011-09-29 2019-04-10 Seattle Genetics Inc Determination of the intact mass of protein-conjugated compounds
US20140242654A1 (en) 2013-02-26 2014-08-28 Coskata, Inc. Butyrate Producing Clostridium species, Clostridium pharus
WO2014150094A1 (en) 2013-03-15 2014-09-25 University Of Florida Research Foundation, Inc. Butyrogenic bacteria as probiotics to treat clostridium difficile
KR101470995B1 (en) * 2013-08-30 2014-12-09 주식회사 바이오리쏘스 Propionic acid producing microorganism and roughage comprising the same
AU2016205975B2 (en) 2015-01-09 2021-05-27 Wageningen Universiteit Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases
CN108699509A (en) 2015-12-31 2018-10-23 卡勒斯制药有限公司 Culture and the method for preserving Eubacterium hallii
SG11201807023QA (en) 2016-02-25 2018-09-27 Caelus Pharmaceuticals B V Compositions and methods for preventing and/or treating vitamin b12 deficiency

Also Published As

Publication number Publication date
BR112018017233A2 (en) 2019-01-15
RU2018133333A (en) 2020-03-25
AU2017222990A1 (en) 2018-09-20
US10857189B2 (en) 2020-12-08
JP7012651B2 (en) 2022-01-28
EP3419637B1 (en) 2021-01-27
WO2017146580A1 (en) 2017-08-31
RU2018133333A3 (en) 2020-03-25
EP3419637A1 (en) 2019-01-02
US20190038678A1 (en) 2019-02-07
ES2865477T3 (en) 2021-10-15
JP2019506413A (en) 2019-03-07
JP2022031800A (en) 2022-02-22
JP7219801B2 (en) 2023-02-08
KR20180113535A (en) 2018-10-16
CN108697742A (en) 2018-10-23
CA3014525A1 (en) 2017-08-31
RU2730870C2 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
SG11201807023QA (en) Compositions and methods for preventing and/or treating vitamin b12 deficiency
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201901986SA (en) Process for the manufacture of a solid pharmaceutical adminstration form
SG11201805001UA (en) Method of treating influenza a
SG11201900361RA (en) Methods of treating prostate cancer
SG11201804587QA (en) Isoindole compounds
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201901394XA (en) Neisseria meningitidis vaccine